Skip to main content

Site notifications

Notice for leniolisib (Pharming Australia Pty Ltd)

Active ingredients
leniolisib
Date of review outcome
Lapse date
Type
Orphan Drug
Dosage form(s)
film-coated tablet
Indication
For the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in children aged 4 to 11 years
Therapeutic area
Immunology